Sandra Wiley

Sandra Wiley

Company: MEI Pharma

Job title: Director of Translational Science

Seminars:

Full Audience Activity – Roundtable Discussion 3:30 pm

At your table discuss the following questions: What are the 3 most important factors to consider when selecting your modality of choice? In your mind, what are the central pros of a PROTAC degrader vs a traditional inhibitor? What feature would you prioritize as your ‘dealbreaker’ when making a final decision regarding modality?Read more

day: Day One

Expert Panel Discussion: To Degrade or Not to Degrade – Rationale Behind Selecting Inhibitory or Degradation Modality 3:00 pm

Highlighting the advantages of using a degrader vs. catalytic site inhibitors and optimizing PKPD Optimizing the linker, linage and E3 ligand for maximal binding and optimizing residency time Discussing the issues of translating degradation efficiency to the clinic with different kinase inhibitorsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.